All In Biotech

Drug Trial Radar · NCT04639050

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

A Phase Ib/IIa, Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose, Parallel-Group Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Patients With Prodromal or Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 241 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

241

Actual

Start

Mar 15, 2021

Primary completion

Jul 31, 2027

Study completion Jul 31, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.

Conditions

  • Alzheimers Disease

Interventions

  • RO7126209Drug

    RO7126209 will be administered intravenously as specified in each treatment arm.

  • PlaceboDrug

    RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1, 2, 3, and 4: Percentage of Participants With Adverse Events (AEs)Time frame: Part 1 and 2: Up to approximately 56 weeks; Part 3: Up to approximately 52 weeks; Part 4: Up to approximately 233 weeks
  2. Part 3: Change From Baseline in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) ScanTime frame: Up to approximately 24 weeks

Locations

37 sites in 9 countries. Site status is shown where the registry gives one.

  • JEM Research LLC

    Atlantis, Florida

  • K2 Medical Research-Winter Garden

    Clermont, Florida

  • K2 Medical Research - The Villages

    Lady Lake, Florida

  • K2 Medical Research, LLC

    Maitland, Florida

  • Optimus U Corp

    Miami, Florida

  • Charter Research - Winter Park/Orlando

    Orlando, Florida

  • Alzheimer's Research and Treatment Center

    Stuart, Florida

  • Charter Research - Lady Lake/The Villages

    The Villages, Florida

  • Alzheimer?s Research and Treatment Center

    Wellington, Florida

  • Conquest Research, LLC

    Winter Park, Florida

  • Alzheimer's Research and Treatment Center - Columbus

    Columbus, Georgia

  • Center for Advanced Research & Education

    Gainesville, Georgia

  • Quest Research Institute

    Farmington Hills, Michigan

  • Abington Neurological Associates

    Abington, Pennsylvania

  • Kerwin Research Center, LLC

    Dallas, Texas

  • Heidelberg Repatriation Hospital

    Heidelberg West, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Richmond Clinical Trials

    Richmond, British Columbia, Canada

  • Toronto Memory Program

    Toronto, Ontario, Canada

  • Centro de Investigación Clínica UC-CICUC

    Santiago, Chile

  • Hospital Clinico Univ de Chile

    Santiago, Chile

  • Koseikai Takeda Hospital

    Kyoto, Japan

  • National Hospital Organization Utano National Hospital

    Kyoto, Japan

  • Keio University Hospital

    Tokyo, Japan

  • Tokyo Metropolitan Institute for Geriatrics and Gerontology

    Tokyo, Japan

  • Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital

    Tokyo, Japan

  • Osrodek Badan Klinicznych Euromedis

    Szczecin, Poland

  • NZOZ WCA

    Wroc?aw, Poland

  • Inha University Hospital

    Incheon, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Fundación ACE

    Barcelona, Spain

  • Hospital Clinic i Provincial

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Dr. Peset

    Valencia, Spain

  • Hospital General De Catalunya

    Sant Cugat del Vallès, Barcelona, Spain

  • Policlínica Guipuzcoa

    Donostia / San Sebastian, Guipuzcoa, Spain

  • UCL Institute of Neurology

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.